Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

The present disclosure relates to paper microfluidic devices for use in combination with a viewing box assembly for imaging and rapid identification and quantification of target analytes in a fluid sample that is deposited onto the device such that one or more target analytes in the sample react with one or more diagnostic components on the paper, causing a detectable reaction. The reacted microfluidic device may then be placed inside an opaque viewing box having an internal light source and top panel viewing aperture through which the microfluidic device may be imaged using a mobile electronic device and graphical user-interface for purposes of detecting and quantifying the one or more target analytes. In some embodiments, the microfluidic device includes diagnostic paper and abase. In some embodiments, the microfluidic device includes a filter layer on top of diagnostic paper layer.

The present disclosure relates to paper microfluidic devices for use in combination with a viewing box assembly for imaging and rapid identification and quantification of target analytes in a fluid sample that is deposited onto the device such that one or more target analytes in the sample react with one or more diagnostic components on the paper, causing a detectable reaction. The reacted microfluidic device may then be placed inside an opaque viewing box having an internal light source and top panel viewing aperture through which the microfluidic device may be imaged using a mobile electronic device and graphical user-interface for purposes of detecting and quantifying the one or more target analytes. In some embodiments, the microfluidic device includes diagnostic paper and abase. In some embodiments, the microfluidic device includes a filter layer on top of diagnostic paper layer.

The present invention relates to a method of enriching or screening for one or more target molecules from a primary source, which method comprises to provide at least one peptidic ligand comprising at least one lysine (K) and immobilized to a solid support; contacting the ligand(s) with a primary source comprising at least one target molecule comprising glutamine (Q); allowing the formation of complexes between the ligand and the target molecule; and separating the complexes from the primary source. The target molecule(s) comprises glutamine, and step c is performed in the presence of a catalytic protein comprising transglutaminase (TG). The catalytic protein comprising transglutaminase (TG) may comprise transglutaminase originating from fish, such as Atlantic cod TG (AcTG), e.g. AcTG-1, and the primary source may include waste material from the fish or dairy industry.

The present invention relates to a method of enriching or screening for one or more target molecules from a primary source, which method comprises to provide at least one peptidic ligand comprising at least one lysine (K) and immobilized to a solid support; contacting the ligand(s) with a primary source comprising at least one target molecule comprising glutamine (Q); allowing the formation of complexes between the ligand and the target molecule; and separating the complexes from the primary source. The target molecule(s) comprises glutamine, and step c is performed in the presence of a catalytic protein comprising transglutaminase (TG). The catalytic protein comprising transglutaminase (TG) may comprise transglutaminase originating from fish, such as Atlantic cod TG (AcTG), e.g. AcTG-1, and the primary source may include waste material from the fish or dairy industry.

An object of the present invention is to provide a blood analysis method and a blood test kit, which are for performing quantitative analysis of components by precisely obtaining a dilution factor. According to the present invention, provided is a blood analysis method including a step of diluting a collected blood sample with a diluent solution; a step of determining a dilution factor by using a normal value of a normal component which is homeostatically present in blood; and a step of analyzing a concentration of a target component in the blood sample, in which the blood analysis method uses a member selected from the group consisting of a first storing instrument for storing a diluent solution, a separation instrument for separating and recovering blood plasma from the blood sample diluted with the diluent solution, a holding instrument for holding the separation instrument, a second storing instrument for storing the recovered blood plasma, and a sealing instrument for keeping the stored blood plasma within the second storing instrument, in which the diluent solution defines an amount of the normal component which is derived from the diluent solution and/or the members and may be contained in the diluent solution, and in which a volume of the blood sample is 50 L or less, and a dilution factor of a blood plasma component in the blood sample is 14 times or more.

An object of the present invention is to provide a blood analysis method and a blood test kit, which are for performing quantitative analysis of components by precisely obtaining a dilution factor. According to the present invention, provided is a blood analysis method including a step of diluting a collected blood sample with a diluent solution; a step of determining a dilution factor by using a normal value of a normal component which is homeostatically present in blood; and a step of analyzing a concentration of a target component in the blood sample, in which the blood analysis method uses a member selected from the group consisting of a first storing instrument for storing a diluent solution, a separation instrument for separating and recovering blood plasma from the blood sample diluted with the diluent solution, a holding instrument for holding the separation instrument, a second storing instrument for storing the recovered blood plasma, and a sealing instrument for keeping the stored blood plasma within the second storing instrument, in which the diluent solution defines an amount of the normal component which is derived from the diluent solution and/or the members and may be contained in the diluent solution, and in which a volume of the blood sample is 50 L or less, and a dilution factor of a blood plasma component in the blood sample is 14 times or more.

A coupled enzyme reaction point of care assay system detects and measures an active enzyme biomarker from a patient's blood sample. The assay system has a point of care blood collector for collecting blood into a blood collection vial. A biomarker detection mechanism has at least three fluid flow entities. Each fluid flow entity has a fluid input zone and a corresponding reaction zone. The fluid flow entities include a test strip, a negative control strip and a positive control strip. The reaction zones include components from a multiplicity of substrates, co-factors, buffers and cryoprotectants, and a multiplicity of tethered enzymes. At least one of the tethered enzymes is an enzyme that produces luminescence. The tethered enzymes are adapted to react to a constituent which may be a biomarker. A photonic luminescence reader measures light emitted from an active enzyme biomarker present in the patient's blood.

A coupled enzyme reaction point of care assay system detects and measures an active enzyme biomarker from a patient's blood sample. The assay system has a point of care blood collector for collecting blood into a blood collection vial. A biomarker detection mechanism has at least three fluid flow entities. Each fluid flow entity has a fluid input zone and a corresponding reaction zone. The fluid flow entities include a test strip, a negative control strip and a positive control strip. The reaction zones include components from a multiplicity of substrates, co-factors, buffers and cryoprotectants, and a multiplicity of tethered enzymes. At least one of the tethered enzymes is an enzyme that produces luminescence. The tethered enzymes are adapted to react to a constituent which may be a biomarker. A photonic luminescence reader measures light emitted from an active enzyme biomarker present in the patient's blood.